Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 1:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3169–3192 of 185,116 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: NOT program Clear all

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Carfilzomib, Chemosensitivity Assay, Dexamethasone, Laboratory Biomarker Analysis, Panobinostat; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Smoking, Nicotine Dependence
Interventions: Nicotine e-cigarette, Non-nicotine e-cigarette; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Gastric Cancer
Interventions: Rilotumumab, Placebo, Epirubicin, Cisplatin, Capecitabine; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 16
States / cities: Tucson, Arizona • Aurora, Colorado • Pueblo, Colorado + 13 more

Conditions: Brain Tumor, Brain Neoplasms, Brain Cancer, Glioma, Glioblastoma
Interventions: Ultrasound; Diagnostic Test
Lead sponsor: Hospital del Rio Hortega; Other
Eligibility: 15 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: GP2013 - A Proposed biosimilar rituximab, Originator rituximab - Rituxan ® or MabThera ®; Biological
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 39
States / cities: Huntsville, Alabama • Tuscaloosa, Alabama • Glendale, Arizona + 33 more

Conditions: Overactive Bladder
Interventions: Belladonna and Opium Suppository, Rectal Exam; Drug · Procedure
Lead sponsor: Campbell Grant; Other
Eligibility: 18 Years to 89 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Venous Leg Ulcer, Venous Stasis Ulcers
Interventions: HP802-247, Placebo (Vehicle); Biological
Lead sponsor: Healthpoint; Industry
Eligibility: 18 Years and older
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 29
States / cities: Tucson, Arizona • Castro Valley, California • Encinitas, California + 26 more

Conditions: Focal Epilepsy
Interventions: Acoustic Stimulation (AS), SHAM Stimulation; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 40 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Scoliosis Idiopathic, Scoliosis; Juvenile
Interventions: Ultrasound; Device
Lead sponsor: Children's National Research Institute; Other
Eligibility: 7 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Mild Cognitive Impairment, Alzheimer Disease
Interventions: Spironolactone, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 50 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension
Interventions: Semaglutide Pen Injector; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Rectal Cancer
Interventions: DCSZ11, Radiation, Capecitabine, Oxaliplatin; Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obesity, Osteoarthritis
Interventions: Vest, Diet; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 65 Years to 79 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Avoidant/Restrictive Food Intake Disorder (ARFID)
Interventions: mCBT-AR; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Eosinophilic Gastritis or Gastroenteritis
Interventions: Benralizumab, Placebo; Biological
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 12 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Treatment Induced Hypertension
Interventions: Minoxidil, Hydralazine; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Homozygous Familial Hypercholesterolemia (HoFH)
Interventions: AAV directed hLDLR gene therapy; Genetic
Lead sponsor: REGENXBIO Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 5
States / cities: Boca Raton, Florida • Kansas City, Kansas • Portland, Oregon + 2 more

Conditions: Ovarian Autotransplantation Using Cryopreserved Ovarian Tissue in Women Treated for Cancer
Interventions: Ovarian autotransplantation; Procedure
Lead sponsor: Samuel Kim, MD; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Psoriasis
Interventions: Risankizumab, Apremilast; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 26
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 22 more

Conditions: Lichen Sclerosus of Vulva
Interventions: Nemolizumab 30 mg; Biological
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: See One, Do One, Order One
Interventions: See One, Do One, Order One; Behavioral
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 1,211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Microsatellite Instability High, Mismatch Repair Deficiency, Colorectal Cancer
Interventions: RT and Anti-PD-1, Anti-PD-1; Combination Product · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: HDAC inhibitor AR-42, decitabine, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: Alison Walker; Other
Eligibility: 3 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Cincinnati, Ohio • Columbus, Ohio

Conditions: Lymphoma
Interventions: rituximab, cisplatin, cytarabine, dexamethasone, sargramostim; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 20
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 17 more

Search by objective public record fields.

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Short Term Effects of Electronic Cigarettes in Tobacco Dependent Adults

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Brain Tumor Intraoperative Ultrasound Database

GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®

Timing of B and O Suppositories to Help Relieve Post-operative Bladder Spasms

Dose Finding Study of HP802-247 in Venous Leg Ulcers

Sleep Architecture & Cognition in Focal Epilepsy

Ultrasound for Scoliosis Diagnostic Evaluation

Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia

Feasibility of Semaglutide in Advanced Lung Disease

Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer

Arthritis Pilot for Preserving Muscle While Losing Weight

Development and Testing of a Mobile App to Scale Delivery of Cognitive-behavioral Therapy for Avoidant/Restrictive Food Intake Disorder

Benralizumab for Eosinophilic Gastritis (BEGS)

Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension

A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)

Human Ovarian Autotransplantation

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

Nemolizumab for LS

Three Strategies for Implementing Motivational Interviewing on Medical Inpatient Units

Anti-PD-1 +/- RT for MSI-H Solid Tumors

AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia

Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma